- Home
- ACET vs DTIL Comparison
ACET vs DTIL Comparison
Compare ACET & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACET | DTIL |
|---|---|---|
| Founded | 1947 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 97.7M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACET | DTIL |
|---|---|---|
| Price | $7.24 | $4.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $65.33 | $60.00 |
| AVG Volume (30 Days) | ★ 182.8K | 154.1K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 59.82 | ★ 106.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $3.53 |
| 52 Week High | $9.05 | $8.82 |
Technical Indicators
Market Signals| Indicator | ACET | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 59.29 |
| Support Level | $0.62 | $4.17 |
| Resistance Level | $8.46 | $4.61 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 73.50 | 94.34 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.